Norwegian version of this page

Kidney Transplantation

The group initiates and participates in studies focusing on renal transplant patients. The research is clinically oriented towards these patients.

About the group

Clinical studies are oriented on outcomes and complications after kidney and pancreas transplantation including epidemiological studies, RCT’s and explanatory studies of mechanisms and pathogenesis.

The studies include immunotherapy and pharmacokinetics and pharmacotherapeutic modelling. For epidemiological studies local biobank and follow up via Norwegian Renal Registry are essential.

Projects

  • Post-transplant diabetes
  • Fatty acid and transplantation outcomes
  • Kidney rejection and immunity
  • Osteoporosis after transplantation
  • Visceral fat and inflammation
  • Individualization of immunosuppression
  • Biomarkers of outcomes after transplantation
  • Adherence od immunosuppressive treatment
  • Pregnancy and transplantation
  • Estimated glomerular filtration rate
  • Pancreas and islet transplantation

Cooperation

Internal

  • Section of Endocrinology
  • Section of Transplant surgery
  • Department of Pathology
  • Department of Immunology
  • Department of Pediatrics

National

  • Prof. My Svensson, AHUS, UiO
  • University of Tromsø- Renal research Group
  • University of Bergen- Department of nephrology
  • University of Stavanger, Department of nephrology
  • School of Pharmacy, UiO
  • Department of Nutrition, UiO

International

  • Laboratory for Applied Pharmacokinetics and Bioinformatics, University of Southern California
  • Barcelona
  • Prof. A. Jardin, Univ of  Glasgow
  • Prof. Bengt Fellstrøm, University of Uppsala
  • CHU Limoges, Department of Pharmacology and Toxicology, Limoges, France
  • Andreas Paasch, Caltec, Basel.
  • Professor Filip Knop, Center for Diabetes Research, Gentofte Hospital, Copenhagen
  • Professor Bo Feldt-Rasmussen, Department of Nephrology, Rigshospitalet, Copenhagen

Publications

  • Midtvedt K, Åsberg A. Mycophenolate acid and balancing the risk for male allograft recipients. Transplantation [Letter] 2017; 101(1): e39.
  • von Düring ME, Jenssen T, Bollerslev J, Åsberg A, Godang K, Hartmann A. Visceral fat is strongly associated with glucose metabolism and post-transplant diabetes mellitus one year after kidney transplantation. Clin Transplant 2017; 31(1): e12869.
  • Vestland TL, Åsberg A, Klaveness AaJ, Klaveness J. Bioavailability of EPA and DHA from Omega-3 Tablets. JSM Bioavailability and Bioequivalence 2017; 1(1): 1001.
  • Rose J, Emery VC, Kumar D, Åsberg A, Hartmann A, Jardine AG, Bignamini AA, Humar A, Neumann AU. Novel decay dynamics revealed for virus mediated drug activation in cytomegalovirus infection. PLOS Pathogens 2017; 13(4): e1006299.
  • Eide IA, Åsberg A, Svensson M, Ueland T, Mollnes TE, Hartmann A, Bjerve KS, Michelsen A, Aukrust P, Christensen JH, Schmidt EB, Jenssen T. Plasma levels of marine n-3 fatty acids are inversely correlated with pro-inflammatory markers sTNFR1 and IL-6 in renal transplant recipients. J Renal Nutr 2017; 27(3): 161-168.
  • Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A. Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance. Br J Clin Pharmacol [Letter] 2017; 83(6): 1350-1352.
  • Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A. Response to: Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance. Br J Clin Pharmacol [Letter] 2017; 83(6): 1357-1358.
  • Pippias M, Kramer A, Noordzij M, Alonso de la Torre R, Ambühl PM, Aparicio MMI, Arribas Monzón F, Åsberg A, Bonthuis M, Bouzas Caamaño E, Bubic I, Caskey FJ, Castro de la Nuez P, Cernevskis H, de los Ángeles GBM, des Grottes J-M, Fernández GR, Ferrer-Alamar M, Finne P, Garneata L, Golan E, Heaf JG, Hemmelder MH, Idrizi A, Ioannou K, Jarraya F, Kantaria N, Kolesnyk M, Kramar R, Lassalle M, Lezaic VV, Lopot F, Macario F, Magaz A, Martín de Francisco AL, Martín EE, Martínez Castelao A, Metcalfe W, Moreno Alia I, Nordio M, Ots-Rosenberg M, Palsson R, Ratkovic M, Resic H, Rutkowski B, Santiuste de Pablos C, Seyahi N, Slon Roblero MF, Spustova V, Stas Koenraad JF, Stendahl Mara E, Stojceva-Taneva O, Vazelov E, Ziginskiene E, Massy Z, Jager KJ, and Stel Vianda S. The European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2014: A summary. Clin Kidney J 2017; 10(2): 154-169.
  • Eide IA, Halden TAS, Hartmann A, Åsberg A, Dahle DO, Jenssen TG. Associations between posttransplantation diabetes mellitus and renal graft survival. Transplantation 2017; 101(6): 1282-1289.
  • García-Carro C, Dörje C, Åsberg A, Midtvedt K, Reinholt FP, Strøm EH, Holdaas H, Serón D, Reisæter AV. Inflammation in early kidney allograft surveillance biopsies and its relationship with de novo donor specific antibodies. Transplantation 2017; 101(6): 1410-1415.
  • Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A. The CYP3A biomarker 4ß-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. Br J Clin Pharmacol 2017; 83(7): 1457-1465.
  • Midtvedt K, Bergan S, Reisæter AV, Vikse BE, Åsberg A. Exposure to mycophenolate and fatherhood. Transplantation 2017; 101(7); e214-e217.
  • Midtvedt K, Holdaas H, Bergan S, Åsberg A. Costimulation blockade; America first, Canada second…….but what about Norway? Am J Transplant [Letter] 2017; 17(8): 2230.
  • Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Størset E, Gustavsen MT, Reisæter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Åsberg A. High tacrolimus clearance is a risk factor for acute rejection in the early phase after renal transplantation. Transplantation 2017; 101(8): e273-e279.
  • Apeland T, Danielsen T, Åsberg A, Dalsrud TO, Staal EM, Thorsen IM, Ørn S. Risk factors for exertional rhabdomyolysis with renal stress. BMJ Open Sport & Exercise Medicine 2017; 3(1): e000241.
  • Torres IB, Reisæter AV, Moreso F, Åsberg A, Vidal M, Garcia-Carro C, Midtvedt K, Reinholt FP, Scott H, Castella E, Salcedo M, Dörje C, Sellares J, Azancot MA, Perello M, Holdaas H, Seron D. Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants. Transplant Int 2017; 30(11): 1119-1131.
  • Åsberg A, Robertsen I, Midtvedt K. How to report and interpret bioequivalence data in solid organ transplant recipients. Transplantation [Letter] 2017; 101(11): e347.
  • Hole K, Størset E, Olastuen A, Haslemo T, Kro GB, Midtvedt K, Åsberg A, Molden E. Rapid recovery of CYP3A phenotype following kidney transplantation. Drug Metabol Disp 2017; 45(12): 1260-1265.
  • Salvador CL, Hartmann A, Åsberg A, Rowe AD, Mørkrid L. Estimating glomerular filtration rate in kidney transplant recipients; comparing a novel equation with commonly used equations in this population. Transplantation Direct 2017; 3: e332.
  • Dupont L, Eide IA, Hartmann A, Christensen JH, Åsberg A, Jenssen T, Krarupm H, Svensson M. Haptoglobin 2-2 genotype, patient and graft survival in renal transplant recipients. Progress in Transplantation 2017; 27(4): 386-391.
  • Smerud KT, Åsberg A, Kile H, Pasch A, Dahle DO, Bollerslev J, Godang K, Hartmann A. A rapid and sustained improvement of calcification propensity score after successful kidney transplantation: reanalysis of a randomized controlled trial of ibandronate. Clin Transplant 2017; 31(12): e13131.
  • Koefoed-Nielsen P, Weinreich I, Bengtsson M, Lauronen J, Naper C, Gäbel M, Sørensen SS, Wennberg L, Reisaeter AV, Møller BK; Nordic Kidney group and the Tissue Typing group in Scandiatransplant. Scandiatransplant acceptable mismatch program (STAMP) a bridge to transplanting highly immunized patients. HLA. 2017: 17-24
  • Majak GB, Reisæter AV, Zucknick M, Lorentzen B, Vangen S, Henriksen T, Michelsen TM. Preeclampsia in kidney transplanted women; Outcomes and a simple prognostic risk score system. PLoS One. 2017; 12(3): e0173420.
  • Dahle DO, Grotmol T, Leivestad T, Hartmann A, Midtvedt K, Reisæter AV, Mjøen G, Pihlstrøm HK, Næss H, Holdaas H. Association Between Pretransplant Cancer and  Survival in Kidney Transplant Recipients. Transplantation. 2017; 101(10): 2599-2605.
  • Heldal K, Hartmann A, Lønning K, Leivestad T, Reisæter AV, Line PD, Holdaas H, Midtvedt K. Should patients older than 65 years be offered a second kidney transplant? BMC Nephrol. 2017; 18(1): 13.
  • van den Brand JAJG, Pippias M, Stel VS, Caskey FJ, Collart F, Finne P, Heaf J, Jais JP, Kramar R, Massy ZA, De Meester J, Traynor JP, Reisæter AV, Wetzels JFM,  Jager KJ. Lifetime risk of renal replacement therapy in Europe: a population-based study using data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2017; 32(2): 348-355.
  • Bremer S, Vethe NT, Skauby M, Kasbo M, Johansson ED, Midtvedt K, Bergan S. NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation. Br J Clin Pharmacol. 2017; 83(11): 2494-2502.
  • Pihlstrøm HK, Gatti F, Hammarström C, Eide IA, Kasprzycka M, Wang J, Haraldsen G, Svensson MHS, Midtvedt K, Mjøen G, Dahle DO, Hartmann A, Holdaas H. Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study. Transpl Int. 2017; 30(8): 827-840.
  • Lindahl JP, Massey RJ, Hartmann A, Aakhus S, Endresen K, Günther A, Midtvedt K, Holdaas H, Leivestad T, Horneland R, Øyen O, Jenssen T. Cardiac Assessment of Patients With Type 1 Diabetes Median 10 Years After Successful Simultaneous Pancreas and Kidney Transplantation Compared With Living Donor Kidney Transplantation. Transplantation. 2017; 101(6): 1261-1267
  • Rizvi SMH, Aagnes B, Holdaas H, Gude E, Boberg KM, Bjørtuft Ø, Helsing P, Leivestad T, Møller B, Gjersvik P. Long-term Change in the Risk of Skin Cancer After Organ Transplantation: A Population-Based Nationwide Cohort Study. JAMA Dermatol. 2017; 153(12): 1270-1277.
  • Mjøen G, Holdaas H. Long term risk of mortality after living kidney donation.  BMJ. 2017; 357: j1770.
  • Holdaas H, Mjøen G, Jardine AG. Belatacept: Where the BENEFITS Outweigh the Risk. Am J Kidney Dis. 2017; 69(5): 561-563.
  • Mjøen G, Holdaas H. Regarding "Obesity increases the risk of end-stage renal disease among living kidney donors". Kidney Int. 2017; 91(5): 1256.
  • Holdaas H, de Fijter JW, Cruzado JM, Massari P, Nashan B, Kanellis J, Witzke O, Gutierrez-Dalmau A, Turkmen A, Wang Z, Lopez P, Bernhardt P, Kochuparampil J,  van der Giet M, Murbraech K; ELEVATE Study Group. Cardiovascular Parameters to 2  years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy: An Analysis of the Randomized ELEVATE Study. Transplantation. 2017; 101(10): 2612-2620.
  • Norby GE, Mjøen G, Bjørneklett R, Vikse BE, Holdaas H, Svarstad E, Aasarød K.  Outcome in biopsy-proven Lupus nephritis: Evaluation of biopsies from the Norwegian Kidney Biopsy Registry. Lupus. 2017; 26(8): 881-885.
  • de Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ, Sommerer C, Pascual J, Avihingsanon Y, Pongskul C, Oppenheimer F, Toselli L, Russ G, Wang  Z, Lopez P, Kochuparampil J, Cruzado JM, van der Giet M; ELEVATE Study Group. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. Am J Transplant. 2017; 17(7): 1853-1867.
  • Wagner S, Apetrii M, Massy ZA, Kleber ME, Delgado GE, Scharnagel H, März W, Metzger M, Rossignol P, Jardine A, Holdaas H, Fellström B, Schmieder R, Stengel B, Zannad F; on behalf AURORA study group and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) network. Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. Free Radic Res. 2017; 51(1): 14-23.
  • Pihlstrøm HK, Mjøen G, Mucha S, Haraldsen G, Franke A, Jardine A, Fellström B, Holdaas H, Melum E. Single Nucleotide Polymorphisms and Long-Term Clinical Outcome in Renal Transplant Patients: A Validation Study. Am J Transplant. 2017; 17(2): 528-533.
  • Meyer KB, Hartmann A, Mjøen G, Andersen MH. Relationships Between Clinical, Self-Reported, and Donation Specific Outcomes: A Prospective Follow-up Study 10 Years After Kidney Donation. Ann Transplant. 2017; 22: 148-155.
  • Jenssen T, Hartmann A, Birkeland KI. Long-term diabetes complications after pancreas transplantation. Curr Opin Organ Transplant. 2017; 22(4): 382-388.
  • Norvik JV, Schirmer H, Ytrehus K, Storhaug HM, Jenssen TG, Eriksen BO, Mathiesen EB, Løchen ML, Wilsgaard T, Solbu MD. Uric acid predicts mortality and  ischaemic stroke in subjects with diastolic dysfunction: the Tromsø Study 1994-2013. ESC Heart Fail. 2017; 4(2): 154-161.
  • Bethel MA, Hyland KA, Chacra AR, Deedwania P, Fulcher GR, Holman RR, Jenssen T, Levitt NS, McMurray JJV, Boutati E, Thomas L, Sun JL, Haffner SM; NAVIGATOR Study Group. Updated risk factors should be used to predict development of diabetes. J Diabetes Complications. 2017; 31(5): 859-863.
  • Norvik JV, Schirmer H, Ytrehus K, Jenssen TG, Zykova SN, Eggen AE, Eriksen BO, Solbu MD. Low adiponectin is associated with diastolic dysfunction in women: a cross-sectional study from the Tromsø Study. BMC Cardiovasc Disord. 2017; 17(1): 79.
  • Eriksen BO, Stefansson VT, Jenssen TG, Mathisen UD, Schei J, Solbu MD, Wilsgaard T, Melsom T. Blood pressure and age-related GFR decline in the general  population. BMC Nephrol. 2017; 18(1): 77.
  • Eriksen BO, Stefansson VTN, Jenssen TG, Mathisen UD, Schei J, Solbu MD, Wilsgaard T, Melsom T. High Ambulatory Arterial Stiffness Index Is an Independent Risk Factor for Rapid Age-Related Glomerular Filtration Rate Decline in the General Middle-Aged Population. Hypertension. 2017; 69(4): 651-659.
  • Schei J, Stefansson VT, Eriksen BO, Jenssen TG, Solbu MD, Wilsgaard T, Melsom  T. Association of TNF Receptor 2 and CRP with GFR Decline in the General Nondiabetic Population. Clin J Am Soc Nephrol. 2017; 12(4): 624-634.
  • Schive SW, Foss A, Sahraoui A, Kloster-Jensen K, Hafsahl G, Kvalheim G, Lundgren T, von Zur-Mühlen B, Felldin M, Rafael E, Lempinen M, Korsgren O, Jenssen TG, Mishra V, Scholz H. Cost and clinical outcome of islet transplantation in Norway 2010-2015. Clin Transplant. 2017; 31(1): e12871.
  • Kolseth IB, Reine TM, Parker K, Sudworth A, Witczak BJ, Jenssen TG, Kolset SO. Increased levels of inflammatory mediators and proinflammatory monocytes in patients with type I diabetes mellitus and nephropathy. J Diabetes Complications. 2017; 31(1): 245-252.
  • Gagnum V, Stene LC, Jenssen TG, Berteussen LM, Sandvik L, Joner G, Njølstad PR, Skrivarhaug T. Causes of death in childhood-onset Type 1 diabetes: long-term  follow-up. Diabet Med. 2017; 34(1): 56-63.
  • Gagnum V, Stene LC, Leivestad T, Joner G, Skrivarhaug T. Response to Comment on Gagnum et al. Long-term Mortality and End-Stage Renal Disease in a Type 1 Diabetes Population Diagnosed at Age 15-29 Years in Norway. Diabetes Care 2017;40:38-45. Diabetes Care. 2017; 40(9): e125.
  • Gagnum V, Stene LC, Leivestad T, Joner G, Skrivarhaug T. Long-term Mortality and End-Stage Renal Disease in a Type 1 Diabetes Population Diagnosed at Age 15-29 Years in Norway. Diabetes Care. 2017; 40(1): 38-45.
  • Pourteymour S, Hjorth M, Lee S, Holen T, Langleite TM, Jensen J, Birkeland KI, Drevon CA, Eckardt K. Dual specificity phosphatase 5 and 6 are oppositely regulated in human skeletal muscle by acute exercise. Physiol Rep. 2017; 5(19): e13459.
  • Birkeland KI. Populærvitenskapelig om testosteron. Tidsskr Nor Laegeforen. 2017; 137(18).
  • Birkeland KI. Antidiabetika er bare en del av god diabetesbehandling! Tidsskr  Nor Laegeforen. 2017; 137(18).
  • Görgens SW, Benninghoff T, Eckardt K, Springer C, Chadt A, Melior A, Wefers J, Cramer A, Jensen J, Birkeland KI, Drevon CA, Al-Hasani H, Eckel J. Hypoxia in Combination With Muscle Contraction Improves Insulin Action and Glucose Metabolism in Human Skeletal Muscle via the HIF-1α Pathway. Diabetes. 2017; 66(11): 2800-2807.
  • Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M,  Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017; 5(9): 709-717.
  • Risstad H, Kristinsson JA, Fagerland MW, le Roux CW, Birkeland KI, Gulseth HL, Thorsby PM, Vincent RP, Engström M, Olbers T, Mala T. Bile acid profiles over 5 years after gastric bypass and duodenal switch: results from a randomized clinical trial. Surg Obes Relat Dis. 2017; 13(9): 1544-1553.
  • Ofstad AP, Ulimoen GR, Orvik E, Birkeland KI, Gullestad LL, Fagerland MW, Johansen OE. Long-term follow-up of a hospital-based, multi-intervention programme in type 2 diabetes mellitus: impact on cardiovascular events and death. J Int Med Res. 2017; 45(5): 1535-1552.
  • Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A,  Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P;  CVD-REAL Investigators and Study Group*. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017; 136(3): 249-259.
  • Gulseth HL, Wium C, Angel K, Eriksen EF, Birkeland KI. Effects of Vitamin D Supplementation on Insulin Sensitivity and Insulin Secretion in Subjects With Type 2 Diabetes and Vitamin D Deficiency: A Randomized Controlled Trial. Diabetes Care. 2017; 40(7): 872-878.
  • Lund J, Rustan AC, Løvsletten NG, Mudry JM, Langleite TM, Feng YZ, Stensrud C, Brubak MG, Drevon CA, Birkeland KI, Kolnes KJ, Johansen EI, Tangen DS, Stadheim HK, Gulseth HL, Krook A, Kase ET, Jensen J, Thoresen GH. Exercise in vivo marks human myotubes in vitro: Training-induced increase in lipid metabolism. PLoS One. 2017; 12(4): e0175441.
  • Pourteymour S, Eckardt K, Holen T, Langleite T, Lee S, Jensen J, Birkeland KI, Drevon CA, Hjorth M. Global mRNA sequencing of human skeletal muscle: Search  for novel exercise-regulated myokines. Mol Metab. 2017; 6(4): 352-365.
  • Lee S, Norheim F, Gulseth HL, Langleite TM, Kolnes KJ, Tangen DS, Stadheim HK, Gilfillan GD, Holen T, Birkeland KI, Jensen J, Drevon CA. Interaction between plasma fetuin-A and free fatty acids predicts changes in insulin sensitivity in response to long-term exercise. Physiol Rep. 2017; 5(5): e13183.
  • Sletner L, Jenum AK, Yajnik CS, Mørkrid K, Nakstad B, Rognerud-Jensen OH, Birkeland KI, Vangen S. Fetal growth trajectories in pregnancies of European and  South Asian mothers with and without gestational diabetes, a population-based cohort study. PLoS One. 2017; 12(3): e0172946.
  • Moen GH, Sommer C, Prasad RB, Sletner L, Groop L, Qvigstad E, Birkeland KI. MECHANISMS IN ENDOCRINOLOGY: Epigenetic modifications and gestational diabetes: a systematic review of published literature. Eur J Endocrinol. 2017; 176(5): R247-R267.
  • Waage C, Jenum AK, Mdala I, Berg JP, Richardsen K, Birkeland K. Associations between gestational diabetes mellitus and elevated HbA1c early postpartum in a multi-ethnic population. Prim Care Diabetes 2017; 11(2): 132-139.

 

Published Aug. 14, 2018 10:36 AM - Last modified Aug. 15, 2019 1:23 PM

Contact

Group leader

Participants

Detailed list of participants